TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, showing inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% for TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at 10 µM. It exhibits strong antiproliferative and antimigratory effects on prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds potential for research in the field of cancer therapeutics.
Target:
YAP
* VAT and and shipping costs not included. Errors and price changes excepted
